advertisement
Abstract #9899 Published in IGR 5-3
Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma
Camras CB; Hedman K; US Latanoprost Study GroupJournal of Glaucoma 2003; 12: 466-469
PURPOSE: This study determined the rate of response to latanoprost compared with timolol in patients with glaucoma or ocular hypertension, whether some patients convert from non-responders to responders after more prolonged therapy, and whether this conversion represents a delayed response or random fluctuation. METHODS: In a previously described, multicenter, randomized, double-masked, parallel group study, patients received either 0.005% latanoprost once daily (n = 128) or 0.5% timolol twice daily (n = 140) for six months. Intraocular pressure (IOP) was assessed at baseline and at 0.5, 1.5, 3, 4.5, and six months of treatment at 8 am on all visits, and also at noon and 4 pm at baseline and six months. Rate of response based on diurnal measurement at six months compared with baseline was assessed using several criteria for response. Eyes with an IOP reduction of less than 15% compared with baseline at 8 am arbitrarily were classified as non-responders at each of the five visits during treatment. Consistency of non-responder classifications for individual eyes was assessed. RESULTS: Mean IOP reduction was greater (p < 0.001) in latanoprost-versus timolol-treated patients throughout the course of therapy. A greater rate of response occurred in patients treated with latanoprost, and differences in response rates between the two drugs increased as the definitions of response became more stringent. A greater percentage of non-responders at any single visit were classified as responders at all other visits with latanoprost in comparison with timolol. CONCLUSIONS: Latanoprost produces a greater rate of response compared with timolol. A higher percentage of non-responders to latanoprost compared with timolol on any individual visit are responders on all other visits. Likewise, a higher proportion of patients who do not initially respond will become responders with continued treatment with latanoprost compared with timolol.
Dr. C.B. Camras, Department of Ophthalmology, University of Nebraska medical Center, Omaha, NE 68198-5540, USA. cbcamras@unmc.edu
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
